Search

Search Constraints

You searched for: Author/Creator Kelly, S.

Search Results

5. AB0213 Is Disease Duration An Independent Predictor of Low Disease Activity/remission among Biologic-Naïve Patients with Rheumatoid Arthritis Treated with Abatacept?. (15th July 2016)

7. AB0323 Weekly subcutaneous abatacept confers comparable onset of treatment response and magnitude of efficacy improvement over 6 months when administered with or without an intravenous abatacept loading dose. (23rd January 2014)

8. AB0356 TARGETING THE RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLAST VIA CYCLIN DEPENDENT KINASE INHIBITION (TRAFIC): A PHASE 1B STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE OF SELICICLIB FOR REPURPOSING IN RHEUMATOID ARTHRITIS. (2nd June 2020)